<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    14609883
   </pmid>
   <datecreated>
    <year>
     2003
    </year>
    <month>
     11
    </month>
    <day>
     11
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2004
    </year>
    <month>
     02
    </month>
    <day>
     17
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     11
    </month>
    <day>
     03
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0003-990X
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       60
      </volume>
      <issue>
       11
      </issue>
      <pubdate>
       <year>
        2003
       </year>
       <month>
        Nov
       </month>
      </pubdate>
     </journalissue>
     <title>
      Archives of general psychiatry
     </title>
     <isoabbreviation>
      Arch. Gen. Psychiatry
     </isoabbreviation>
    </journal>
    <articletitle>
     Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
    </articletitle>
    <pagination>
     <medlinepgn>
      1079-88
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      Despite the longer duration of the depressive phase in bipolar disorder and the frequent clinical use of antidepressants combined with antipsychotics or mood stabilizers, relatively few controlled studies have examined treatment strategies for bipolar depression.
     </abstracttext>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To examine the use of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      Double-blind, 8-week, randomized controlled trial.
     </abstracttext>
     <abstracttext label="SETTING" nlmcategory="METHODS">
      Eighty-four sites (inpatient and outpatient) in 13 countries. Patients A total of 833 randomized adults with bipolar I depression with a Montgomery-Asberg Depression Rating Scale (MADRS) score of at least 20. Intervention Patients were randomly assigned to receive placebo (n = 377); olanzapine, 5 to 20 mg/d (n = 370); or olanzapine-fluoxetine combination, 6 and 25, 6 and 50, or 12 and 50 mg/d (n = 86).
     </abstracttext>
     <abstracttext label="MAIN OUTCOME MEASURE" nlmcategory="METHODS">
      Changes in MADRS total scores using mixed-effects model repeated-measures analyses.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      During all 8 study weeks, the olanzapine and olanzapine-fluoxetine groups showed statistically significant improvement in depressive symptoms vs the placebo group (P&lt;.001 for all). The olanzapine-fluoxetine group also showed statistically greater improvement than the olanzapine group at weeks 4 through 8. At week 8, MADRS total scores were lower than at baseline by 11.9, 15.0, and 18.5 points in the placebo, olanzapine, and olanzapine-fluoxetine groups, respectively. Remission criteria were met by 24.5% (87/355) of the placebo group, 32.8% (115/351) of the olanzapine group, and 48.8% (40/82) of the olanzapine-fluoxetine group. Treatment-emergent mania (Young Mania Rating Scale score &lt;15 at baseline and &gt; or =15 subsequently) did not differ among groups (placebo, 6.7% [23/345]; olanzapine, 5.7% [19/335]; and olanzapine-fluoxetine, 6.4% [5/78]). Adverse events for olanzapine-fluoxetine therapy were similar to those for olanzapine therapy but also included higher rates of nausea and diarrhea.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      Olanzapine is more effective than placebo, and combined olanzapine-fluoxetine is more effective than olanzapine and placebo in the treatment of bipolar I depression without increased risk of developing manic symptoms.
     </abstracttext>
    </abstract>
    <affiliation>
     Lilly Research Laboratories, Indianapolis, IN 46285, USA. m.tohen@lilly.com
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Tohen
      </lastname>
      <forename>
       Mauricio
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Vieta
      </lastname>
      <forename>
       Eduard
      </forename>
      <initials>
       E
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Calabrese
      </lastname>
      <forename>
       Joseph
      </forename>
      <initials>
       J
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Ketter
      </lastname>
      <forename>
       Terence A
      </forename>
      <initials>
       TA
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Sachs
      </lastname>
      <forename>
       Gary
      </forename>
      <initials>
       G
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Bowden
      </lastname>
      <forename>
       Charles
      </forename>
      <initials>
       C
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Mitchell
      </lastname>
      <forename>
       Philip B
      </forename>
      <initials>
       PB
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Centorrino
      </lastname>
      <forename>
       Franca
      </forename>
      <initials>
       F
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Risser
      </lastname>
      <forename>
       Richard
      </forename>
      <initials>
       R
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Baker
      </lastname>
      <forename>
       Robert W
      </forename>
      <initials>
       RW
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Evans
      </lastname>
      <forename>
       Angela R
      </forename>
      <initials>
       AR
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Beymer
      </lastname>
      <forename>
       Karin
      </forename>
      <initials>
       K
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Dube
      </lastname>
      <forename>
       Sanjay
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Tollefson
      </lastname>
      <forename>
       Gary D
      </forename>
      <initials>
       GD
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Breier
      </lastname>
      <forename>
       Alan
      </forename>
      <initials>
       A
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Arch Gen Psychiatry
    </medlineta>
    <nlmuniqueid>
     0372435
    </nlmuniqueid>
    <issnlinking>
     0003-990X
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antidepressive Agents, Second-Generation
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antipsychotic Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      12794-10-4
     </registrynumber>
     <nameofsubstance>
      Benzodiazepines
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      132539-06-1
     </registrynumber>
     <nameofsubstance>
      olanzapine
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      28797-61-7
     </registrynumber>
     <nameofsubstance>
      Pirenzepine
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      54910-89-3
     </registrynumber>
     <nameofsubstance>
      Fluoxetine
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Arch Gen Psychiatry. 2005 Sep;62(9):1052; author reply 1052
     </refsource>
     <pmid version="1">
      16143737
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="ErratumIn">
     <refsource>
      Arch Gen Psychiatry. 2004 Feb;61(2):176
     </refsource>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antidepressive Agents, Second-Generation
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antipsychotic Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Benzodiazepines
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Bipolar Disorder
     </descriptorname>
     <qualifiername majortopicyn="N">
      diagnosis
     </qualifiername>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Depression
     </descriptorname>
     <qualifiername majortopicyn="N">
      diagnosis
     </qualifiername>
     <qualifiername majortopicyn="N">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Therapy, Combination
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Fluoxetine
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pirenzepine
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      analogs &amp; derivatives
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Psychiatric Status Rating Scales
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2003
     </year>
     <month>
      11
     </month>
     <day>
      12
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2004
     </year>
     <month>
      2
     </month>
     <day>
      18
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2003
     </year>
     <month>
      11
     </month>
     <day>
      12
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     14609883
    </articleid>
    <articleid idtype="doi">
     10.1001/archpsyc.60.11.1079
    </articleid>
    <articleid idtype="pii">
     60/11/1079
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

